Table 3.
Treatment-emergent adverse events (TEAEs) since the initiation of protocol-specified treatment.
| TEAEs, n (%) | Patients (N = 25) |
||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Any grade | |
| Anemia | 19 (76%) | 2 (8%) | 0 | 0 | 21 (84%) |
| Neutropenia | 16 (64%) | 1 (4%) | 2 (8%) | 1 (4%) | 20 (80%) |
| Nausea | 11 (44%) | 3 (12%) | 0 | 0 | 14 (56%) |
| Hand-foot syndrome | 8 (32%) | 6 (24%) | 0 | 0 | 14 (56%) |
| Leukocytopenia | 8 (32%) | 6 (24%) | 0 | 0 | 14 (56%) |
| Aspartate transaminase increased | 7 (28%) | 5 (20%) | 1 (4%) | 0 | 13 (52%) |
| Lipase increased | 12 (48%) | 0 | 0 | 0 | 12 (48%) |
| Proteinuria | 10 (40%) | 0 | 0 | 0 | 10 (40%) |
| Thrombocytopenia | 7 (28%) | 3 (12%) | 0 | 0 | 10 (40%) |
| Vomiting | 9 (36%) | 0 | 0 | 0 | 9 (36%) |
| Hypothyroidism | 7 (28%) | 0 | 0 | 0 | 7 (28%) |
| Triglycerides increased | 6 (24%) | 1 (4%) | 0 | 0 | 7 (28%) |
| Fatigue | 6 (24%) | 1 (4%) | 0 | 0 | 7 (28%) |
| Blood bilirubin increased | 3 (12%) | 3 (12%) | 1 (4%) | 0 | 7 (28%) |
| Alanine transaminase increased | 3 (12%) | 2 (8%) | 2 (8%) | 0 | 7 (28%) |
| Peripheral neurotoxicity | 13 (52%) | 0 | 0 | 0 | 13 (52%) |
| Hoarseness | 5 (20%) | 0 | 0 | 0 | 5 (20%) |
| Rash | 2 (8%) | 1 (4%) | 1 (4%) | 0 | 4 (16%) |
| Thyroiditis | 3 (12%) | 0 | 0 | 0 | 3 (12%) |
| Diarrhea | 2 (8%) | 0 | 0 | 0 | 2 (8%) |
| Troponin increased | 2 (8%) | 0 | 0 | 0 | 2 (8%) |
| Fever | 0 | 2 (8%) | 0 | 0 | 2 (8%) |
| Alkaline phosphatase increased | 1 (4%) | 0 | 0 | 0 | 1 (4%) |
| Amylase increased | 0 | 1 (4%) | 0 | 0 | 1 (4%) |
| Hypertension | 12 (48%) | 2 (8%) | 0 | 0 | 14 (56%) |